Rocket Pharmaceuticals (RCKT) Equity Ratio (2016 - 2025)
Rocket Pharmaceuticals (RCKT) has disclosed Equity Ratio for 10 consecutive years, with 0.84 as the latest value for Q4 2025.
- Quarterly Equity Ratio fell 4.43% to 0.84 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.84 through Dec 2025, down 4.43% year-over-year, with the annual reading at 0.84 for FY2025, 4.43% down from the prior year.
- Equity Ratio hit 0.84 in Q4 2025 for Rocket Pharmaceuticals, down from 0.85 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.92 in Q3 2021 to a low of 0.83 in Q1 2021.
- Historically, Equity Ratio has averaged 0.88 across 5 years, with a median of 0.88 in 2022.
- Biggest five-year swings in Equity Ratio: grew 27.06% in 2021 and later fell 7.31% in 2024.
- Year by year, Equity Ratio stood at 0.91 in 2021, then fell by 3.0% to 0.89 in 2022, then decreased by 1.99% to 0.87 in 2023, then grew by 0.93% to 0.88 in 2024, then decreased by 4.43% to 0.84 in 2025.
- Business Quant data shows Equity Ratio for RCKT at 0.84 in Q4 2025, 0.85 in Q3 2025, and 0.84 in Q2 2025.